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Fax: +34 91 196 4420 
 
 
Abbreviations: AGC1, aspartate-glutamate carrier; COMT, catechol-ortho-methyl-
transferase; DA, dopamine; DARP32, dopamine and cAMP regulated phosphoprotein 
of 32 KDa ; DAT, dopamine transporter; DOPAC, 3,4 dihydroxy-phenyl acetic acid; 
GSH, reduced glutathione; GSSG, oxidized glutathione; 5-HT, serotonin; HVA, 
homovanillic acid; MAO, monoamine oxidase; MAS, malate-aspartate shuttle; 3-MT, 
3-methoxy-tyramine; NA, noradrenaline; NAA, N-acetylaspartate; SERT, serotonin 
transporter; Tyr, tyrosine; PD, Parkinson´s disease; PND, postnatal day; ROS, 
reactive oxygen species; TH, tyrosine hydroxylase; VMAT2, vesicular monoamine 
transporter 2. 
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ABSTRACT 
The mitochondrial transporter of aspartate-glutamate Aralar/AGC1 is a regulatory 
component of the malate-aspartate shuttle. Aralar-deficiency in mouse and human 
causes a shutdown of brain shuttle activity and global cerebral hypomyelination 
associated with a drastic drop in brain aspartate and N-acetylaspartate levels. A lack 
of neurofilament-labelled processes is detected in the cerebral cortex, but whether 
different types of neurons are differentially affected by Aralar-deficiency is still 
unknown. We have now found that Aralar-knockout (Aralar-KO) mice show a general 
delay in neurodevelopment and unexpectedly, hyperactivity, anxiety-like behaviour 
and hyperreactivity. The striatum is the brain region most affected in terms of size, 
amino acid and monoamine content. The DOPAC/dopamine ratio specifically 
increases in striatum but no decrease in dopamine or in the number of nigral 
tyrosine hydroxylase-positive cells was detected in Aralar-KO brainstem.  We find a 
fall in vesicular monoamine transporter-2 (VMAT2) levels associated with an 
increase both in non-vesicular dopamine and dopamine turnover through MAO 
activity. Our results suggest that Aralar-deficiency results in a failure to produce 
mitochondrial NADH and to an increase of ROS in the cytosol causing a fall in 
VMAT2 and GSH/GSSG ratio in striatum. The results indicate that the nigrostriatal 
dopaminergic system is a selective target of Aralar-deficiency. 
 
Key words: malate-aspartate shuttle; AGC-1 deficiency; dopamine; global cerebral 
hypomyelination; VMAT2; OmniBank® 
 
Running title: “Nigrostriatal pathway as a target for AGC-1 deficiency” 
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INTRODUCTION  
Aralar is the brain isoform of the mitochondrial transporter of aspartate/glutamate 
mainly expressed in neurons (del Arco and Satrústegui, 1998; Ramos et al., 2003; 
Pardo et al., 2006, 2011) and its expression is increased during maturation in parallel 
to malate-aspartate shuttle (MAS) activity (Ramos et al., 2003). Aralar deficiency leads 
to a loss of respiration on malate plus glutamate, a shutdown of MAS activity, and a 
drop in brain and neuronal aspartate levels (Jalil et al., 2005). Neurons from Aralar-KO 
mice have a clear metabolic impairment in glucose oxidation due to the lack of a 
functional MAS, which results in an increased lactate production (Pardo et al., 2011). 
In intact cultured neurons, the maximal respiratory capacity of Aralar-KO neurons is 
clearly reduced as compared with control (Gómez-Galán et al., 2011), reflecting the 
limitation in pyruvate supply to mitochondria in the absence of a functional MAS.  
Aralar-KO mice show a drop of N-acetylaspartate (NAA), hypomyelination, and a 
progressive failure to synthesise glutamine in brain astrocytes, suggesting that 
glutamatergic neurotransmission may be compromised in the older animals (Jalil et 
al., 2005; Pardo et al., 2011). These mice present motor problems, tremor, seizures 
and premature death (Jalil et al., 2005). Impaired development or degeneration of 
neuronal processes unrelated to myelin deficits has been observed in Aralar-KO 
mouse brain (Ramos et al., 2011). Besides, a study by Sakurai et al. (2010) showed 
that loss of functional Aralar leads to neurodevelopmental abnormalities in mice. On 
the other hand, in post-mortem brain samples from patients with autism, Aralar has 
been found upregulated in dorsolateral frontal cortex (Palmieri et al., 2008; Lepagnol-
Bestel et al., 2008). And a strong linkage and association of the gene encoding Aralar, 
SLC25A12, with autism, a severe neurodevelopmental disease in humans, has been 
previously reported (Ramoz et al., 2004; Segurado et al., 2005; Turunen et al., 2007).  
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Recently, a patient with an homozygous loss of function mutation in SLC25A12 
was reported to show a loss of mitochondrial respiration on malate plus glutamate, low 
NAA levels, hypomyelination, arrested psychomotor development, hypotonia, and 
seizures (Wibom et al., 2009). These findings are important as the main features of 
aralar deficiency (reduced NAA levels and hypomyelination) are common in mouse 
and human, and support the importance of the Aralar-KO mouse for the study of the 
global cerebral hypomyelination (OMIM ID #612949). To gain insight into the targets 
affected in this early-onset brain disease, we have studied in more detail 
neurodevelopment, motor abilities and general behavior in Aralar-KO mice from 
postnatal day 1 (PND1) to PND22, analyzing neurochemical changes in specific brain 
areas of the Aralar-KO mouse.  
Our data indicate that Aralar-KO mice show a delay in neurodevelopment and 
deficits in motor coordination, ataxic gait, altered geotaxia, increased reactivity, 
hyperactivity and anxiety-like behavior. Interestingly, we have found a pronounced 
decline in the levels of cathecolamines such as dopamine (DA) and serotonin (5-HT). 
The present results reveal a high susceptibility of DAergic neurons, specifically those 
DAergic groups of the nigrostriatal system, to Aralar-MAS dysfunction. A large body of 
evidence supports that nigrostriatal DAergic neurons are highly vulnerable to oxidative 
stress (Mena et al., 1993, 1997; Pardo et al., 1995; Canals et al., 2001), and to 
impairments of energy metabolism (Zeevalk et al., 1997; Pickrell et al., 2011). Our 
results evidence that the striatum is a preferential target of Aralar deficiency which 
leads to a lack of maturation of the GABAergic neurons and a reduction and 
mishandling of DA. Our results suggest a role of oxidative stress caused by Aralar 
deficiency as the origin of dopamine mishandling in striatum. 
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MATERIALS AND METHODS 
 
Methods including animal housing and genotyping, postnatal observations in mice, 
neurobehavioral development and histomorphological studies of muscle are described 
in Supplementary material. 
 
Brain regions and tissue preparation for amino acid analysis 
 Mice at PND19 were anesthetized, the whole brain was immediately removed from 
the skull and the brain regions were dissected according to Carlsson and Lindqvist 
(1973) and Itier et al. (2003) into the dopamine (DA)-rich limbic portion, the corpora 
striata (striatum), diencephalon, brain stem, cerebellum and cerebral cortex. Regions 
were sonicated in 3% perchloric acid (PCA), neutralized, and centrifuged at 10,000 x g 
for 15 min. Supernatants were lyophilized and dissolved in 0.2 M lithium citrate loading 
buffer pH 2.2 for quantification with an automatic amino acid analyzer Biochrom 20 
(Pharmacia, Uppsala, Sweden) using a precolumn derivatization with ninhydrin and a 
cationic exchange column. 
 
 Measurements of monoamines in selected brain regions 
The levels of DA and its metabolites, 3-methoxy-tyramine (3-MT), 3,4 dihydroxy-phenyl 
acetic acid (DOPAC) and homovanillic acid (HVA), noradrenaline (NA) and its 
metabolite, 4-hydroxy-3-methoxy-phenyl-glycol (MHPG), serotonin (5-HT) and its 
metabolite, 5-hydroxy-indole-acetic acid (5-HIAA) were measured by HPLC with an ESA 
coulochem detector, according to Mena et al. (1995). Briefly, samples from the same 
brain regions indicated above were sonicated in 8 volumes (w/v) of 0.4 N perchloric acid 
(PCA) with 0.5 mM Na2S2O5 and 2% EDTA and then centrifuged for 10 min. Monoamine 
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levels were determined from 20 ul of the supernatant. The chromatographic conditions 
were: a column Nucleosil 5C18; the mobile phase, a 0.1 M citrate/acetate buffer, pH 3.9 
with 10% methanol, 1 mM EDTA and 1.2 mM heptane sulfonic acid; and the detector 
voltage conditions: D1 (+0.05), D2 (-0.39) and the guard cell (+0.4). 
 
Western blot in brain tissue 
 Aliquots (20 µg of protein) of brain lysates (in 20 mM Tris-HCl, 10 mM AcK, 1 mM 
DTT, 1 mM EDTA, protease inhibitor cocktail tablet (complete Mini, EDTA-free, 
Roche) 0.25% NP-40, pH 7.4) were centrifuged (12,000 x g, 30 min at 4 ºC) and 
electrophoresed in an 8% SDS acrylamide gel. Proteins were transferred 
electrophoretically to nitrocellulose membranes, which were blocked in 5% (w/v) dry 
skimmed milk (Sveltesse, Nestle) in Tris-buffered saline (10 mM Tris-HCl pH 7.5, 150 
mM NaCl plus 0.05% (v/v) Tween-20) for 2 h, and further incubated with antibodies 
against Aralar (Del Arco and Satrústegui, 1998) (polyclonal antibody, 1:1000), 
dopamine markers (tyrosine hydroxylase, TH polyclonal antibody Millipore, 1:5000; 
dopamine transporter, DAT (SLC6A3) monoclonal antibody Millipore, 1:2000; 
vesicular monoamine transporter, VMAT2 (SLC18A2) polyclonal antibody Millipore 
1:1000; dopamine and adenosine 3´, 5´-monophosphate-regulated phosphoprotein 
(32 kilodaltons), DARPP-32 polyclonal antibody Millipore 1:10000), glial markers 
(GFAP plyclonal antibody Dakopatts 1:500, for astrocytes; and OX-6 monoclonal 
antibody Serotec 1:500, for microglia), and β-actin (monoclonal antibody Sigma 
1:10000), for 1 h at RT. Signal detection was performed with and enhanced 
chemiluminescence substrate (Western lighting-ECL; PerkinElmer). 
 
Statistical analysis  
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 For biochemical data, the statistical significance of the differences was assessed by 
One-way analysis of variance (ANOVA) followed by a post hoc Student’s, 
Duncan/Tukey or Student-Newman-Keuls t-test method, as indicated. The results are 
expressed as mean ± standard error of the mean (s.e.m.). 
 
 
RESULTS  
 
General development, neurodevelopment, psychomotor state and motor 
coordination is altered in Aralar-KO mice 
General development is delayed in Aralar-KO mice (Supplementary). Hyper-
reactivity (Fig. 1A-C), spontaneous convulsions (Fig.1B) and tremor is observed in 
these animals (Supplementary material). 
To evaluate the psychomotor state, social behaviour and motivations, we performed 
the homing test (Fig. 1D). The latency of Aralar wild-type (WT) mice to reach the 
opposite side of the cage stimulated by the presence of the nest was 7.2 ± 1.3 sec, 
showing high motivation to reach the goal. In contrast, Aralar-KO mice did not show 
any displacement toward the target during the test. Since the motor activity, measured 
in the openfield test (Fig. 2), seemed to be intact in Aralar-KO mice, the phenotype 
observed in the homing test may reflect reduced motivation and/or inability to initiate a 
voluntary motor response, one of the signs of basal ganglia dysfunction, particularly 
involving the caudate-putamen (Hauber, 1998; Palmiter, 2008).  
In the acquisition of the surface righting response, WT mice improved the ability 
to upright from PND2 to 11 decreasing the latency from 7.0 ± 1.9 to 1.9 ± 0.04 sec at 
PND11. Aralar-KO mice reached similar latencies at mature stages, but showed a 
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significant impairment in early stages (Fig. 3A). This reflex depends on the 
development of dynamic postural adjustments and implies the integrity of muscular 
and motor function (Altman and Sudarshan, 1975; Dierssen et al., 2002). Acquisition 
of the negative geotaxis reflex (Fig. 3C), a dynamic test that depends on intact 
sensorimotor function (Dierssen et al., 2002), was also dramatically disturbed in KO 
mice. WT animals improved their performance along development, reaching latency 
times around 5 sec, while the KO mice were markedly impaired. Analogous results 
were found in the wire suspension reflex. The fine motricity of the forepaws does not 
appear to be affected in KO mice since this reflex was fully acquired, but significantly 
delayed in Aralar-KO mice (Fig. 3B). All above-mentioned reflexes are sensitive to the 
function of the vestibular system, whose role is to provide information of the position 
and movement of the body and head in space (Altman and Sudarshan, 1975; for 
review, see Smith et al., 2005). Regarding motor development, Aralar-KO mice 
showed a significant delay to acquire adult (walking) versus immature (pivoting) 
locomotor pattern compared with the WT siblings (Fig. 3D).  
The results of the pawprint analysis showed a gait disturbance in Aralar-KO mice 
(Fig. 4A, 4B). KO mice exhibited a significantly shorter stride length and hindpaw 
base width than their WT littermates (Fig. 4A), according to their smaller size, but 
presenting an erratic path (Fig. 4B). Beam balance test clearly demonstrated a motor 
impairment of Aralar-KO mice (Fig. 4C) who tended to lock in a fixed spastic posture 
while on the beam and almost all Aralar-KO mice fell off the bar. The delayed onset  
for the first movement in KO mice on the bar is near the maximum latency estimated 
in the task, 60 sec, while WT mice improved the performance in the second trial 
starting the movement in 26.5 ± 7.8 sec and reaching the end of the beam in 29.3 ± 
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7.5 sec. These motor deficits could be attributable to striatal dysfunction (Menéndez et 
al., 2006; Taylor et al., 2011) or increased anxiety/fear-related responses. 
Thus, in Aralar-KO mice the neuromotor development is significantly delayed. KO 
mice showed a lack of motor coordination in the hindlimbs with no muscle affectation 
(Figure S1), sugestive of a failure in midbrian and/or forebrain structures. 
 
Enhanced locomotor, exploratory activity and emotionality in Aralar-KO mice 
 The open field test, used to study motor activity and anxiety-related behavior in 
mouse (Carola et al., 2001), was assessed in two different environments, in low-
lightening less aversive conditions (with red light) and in high-lightening aversive 
conditions (Fig. 2). Both WT and Aralar-KO were able to perform properly the task at 
PND15-16. Total distance travelled in low-lightening was statistically higher in Aralar-
KO, with strong thigmotaxic behavior (preference to the periphery), compared with WT 
mice (Fig. 2A), indicating a more anxious-like behavior. Aralar-KO mice were as fast 
as WT (mean speed, 8.7± 0.9 cm/sec; Fig. 2B), but with lower resting time (Fig. 2C) 
indicating hyperactivity. In the aversive (high-lightening) condition, Aralar-KO mice 
travelled significantly less distance in periphery than WT and than they did in low-
lightening conditions (Fig. 2A). Moreover, they showed a striking burst of speed in the 
centre of the arena (Fig. 2B). Grooming and fecal boli in the high- vs. low-lightening 
condition were equally increased in all mice, however, the vertical activity (rearing), 
which involves hindlimb strength, tended to be higher in Aralar-KO mice in low-
lightening condition than in WT mice (not shown), and this is also consistent with 
hyperactivity. These results indicate a rise in anxiety-, emotionality-related behaviors 
and reactivity in Aralar-KO animals. 
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Striatum is the main target for AGC1 deficiency  
Although expression of Aralar-AGC1 has been extensively reported to be mainly 
restricted to and highly expressed in brain neurons (Ramos et al., 2003; Berkich et al., 
2007; Xu et al., 2007; Cahoy et al., 2008; Pardo et al., 2011), no neuronal cell death in 
brain from Aralar-KO mice was detected (not shown), but evident hypomyelination 
and loss of neurofilaments was reported occurring in specific brain regions (Jalil et al., 
2005, Sakurai et al., 2010; Ramos et al., 2011). Aralar-KO mice have brain 
abnormalities consisting of a marked enlargement in brain lateral ventricles (Fig. 5A) 
(Jalil et al., 2005), also reported in human AGC-1 deficiency (Wibom et al., 2009). 
Figure 5 shows that the enlargement of lateral ventricles is related to a reduction in the 
size of striatum. Thus, the striatum/brain ratio size was significantly reduced to 80% in 
Aralar-KO mice versus WT (13.33 ± 0.04 % and 10.76 ± 0.03 % in WT and Aralar-KO, 
respectively; p = 0.0286); while the hippocampus/brain ratio size was unchanged 
(11.77 ± 0.02 and 12.74 ± 0.02 % in WT and Aralar-KO, respectively; Fig. 5B). 
Interestingly, the AGC1-deficient patient has also a smaller caudate-putamen than 
expected (Wibom et al., 2009).  
 Consistent with a preferential effect of Aralar deficiency in striatum, we found that 
the drop in whole brain Glutamine (Gln) content previously reported (Pardo et al., 
2011) is more prominent in the striatum (Table 1) than in all the other brain regions 
analyzed, reaching 29% of WT levels in Aralar-KO mice. However, in cerebellum and 
particularly in brainstem Gln levels hardly drop, perhaps due to the presence of low 
levels of citrin, a component of malate-aspartate shuttle homologous to Aralar 
(Contreras et al., 2010). Striatal GABA was also significantly reduced to 60% in Aralar-
KO (Table 1), with no changes in all the other brain regions.  
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On the other hand, Table 1 shows that none of the brain regions analyzed differed 
with respect to the drop in whole brain aspartate, serine and alanine levels (Pardo et 
al., 2011).  
Thus, the striatum appeared to be the brain region most affected by aralar deficiency.  
 
Monoamine metabolism is impaired in brain from Aralar-deficient mice  
Given the marked inability of Aralar-KO mice to perform motor tasks and the hyper-
reactivity, hyper-activity and anxiety observed in the tests performed, and the 
prominent effect of Aralar deficiency in the striatum, we decided to investigate the 
metabolism of monoamines in several brain regions, and particularly in striatum, as it 
is closely involved in the former functions (see Stein et al., 2006 for references). 
NA content was similar in WT and Aralar-KO mice in any of the regions studied 
(Table 2).   
Regarding the serotoninergic system, Aralar deficiency resulted in a significant 
decrease both in 5-HT levels and specially those of its intracellular degradation 
product 5-HIAA in diencephalon (to 51% and 43%, respectively, versus control) and 
brainstem (to 72% and 59%, respectively) (Table 2), with similar changes in striatum 
and limbic system (Table 2), which have much lower 5HT content than the former 
areas. Of note, mRNA for serotonin transporter (SERT/Slc6a4), the plasma membrane 
transporter of serotonin which terminates the action of serotonin, is greatly increased 
(5.5-fold of WT value) in Aralar-KO brain (Table S3), suggesting that an increased 
reuptake of this neurotransmitter may be related to a reduced intracellular degradation 
of 5-HT to 5-HIAA through monoamine oxidase (MAO) activity and subsequent 
decrease in 5-HIAA/5HT ratio (Table 3) in brain from Aralar-KO mice. 
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   In the brainstem, where the DAergic neuronal somata of the nigrostriatal pathway 
are located, no obvious change in the number of TH-positive cells was apparent. 
Neither the substantia nigra nor midbrain from Aralar-KO mice showed changes in TH-
immunolabeling (Fig. 5C, 5D) or expression of TH (not shown) as compared to WT. 
Moreover, DA and its metabolites were increased or unchanged in brainstem and 
diencephalon, the major regions enriched in DAergic somata, from Aralar-KO mice 
(Table 2).  
In contrast, Aralar deficiency resulted in changes in DA and its metabolites in the 
regions enriched in DAergic projections, striatum and limbic system. Aralar-KO 
striatum showed a substantial reduction in DA (to 64%) and its metabolites, 3-MT (to 
43%) and HVA (to 68% of controls) (Table 2). However, the content of DOPAC was 
not changed, resulting in a significant increase in DOPAC/DA ratio (138% versus 
control, Table 3). The very low levels of 3-MT (Brown et al., 1991; Wood and Altar, 
1988) in striatum  from Aralar-deficient mice and the increase in the ratio of the MAO-
derived DA metabolite, DOPAC, over the catechol-ortho-methyl-transferase (COMT)-
derived DA metabolites, 3-MT and HVA, in Aralar-KO striatum (DOPAC/HVA, 1.38-
fold of WT and DOPAC/ 3-MT, 2.35-fold of WT; Table 3) suggest an impairment in DA 
release in these animals. As DOPAC formation requires the intraneuronal MAO–
aldehyde dehydrogenase pathway, whereas 3-MT and HVA are formed thanks to 
COMT in postsynaptic neurons or astrocytes (see Fig.  6C), these results also 
suggests an increase in intraneuronal metabolism of DA in Aralar-KO mice. 
Aralar-KO limbic system shows an important reduction in DA (57%) and DOPAC 
(50%); but only a slight decrease in HVA (Table 1).  It is unlikely that DA release is 
particularly diminished in the limbic system, even though 3-MT levels are reduced 
(Table 2), the HVA/DA ratio, which reflects DA turnover via COMT, which functions on 
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the released DA (Rivett et al., 1983), is increased (Table 3).  In addition, the  drop in 
DA content in the limbic system of Aralar-KO mice does not appear to be due to 
increased in intracellular metabolism of DA (DOPAC/DA ratio) (Table 3). 
In conclusion, the Aralar-KO mouse brain shows no changes in NA but a 
significant decrease in serotonin only in diencephalon and brainstem, brain regions 
rich in 5HT neurons.  As for the DA system, although DA and metabolites did not 
change in brain regions rich in DA somata, i.e. diencephalon and brainstem, marked 
decreases in DA were found in areas enriched in DAergic nerve terminals. These 
results (summarized in Fig. 6A) suggest a clear decrease in DA release and increase 
in DA intracellular metabolism in striatum, but no obvious changes in turnover or 
release in the limbic system.  
 
DA markers of presynaptic and postsynaptic terminals in striatum and limbic 
system 
A further analysis for DA markers in striatum and limbic system, is shown in Fig 
6D-F. Remarkably, there is a significant reduction of the DAergic markers VMAT2, the 
presynaptic vesicular transporter of monoamines,  and DARPP32, the dopamine and 
cAMP regulated phosphoprotein of 32 kDa present in striatal  postsynaptic medium 
spiny neurons (Fienberg et al., 1998) in striatum (Fig. 6E), but not in the limbic system 
(Fig 6F) of Aralar-KO mice. However, no changes in TH and the dopamine transporter 
DAT were found in striatum from Aralar-KO mice indicating no gross modifications in 
the density of presynaptic DAergic terminals. The content of GFAP and OX6 as gliosis 
markers was unchanged in Aralar-deficient striatum compared to controls (not 
shown). 
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     DARPP32 is mainly expressed in mature medium spiny neurons which are 
GABAergic (Fienberg et al., 1998). We have previously noted a 40% decrease in 
striatal GABA levels in Aralar-KO mice (Table 1). However, the remarkable lack of 
postsynaptic DARPP32 in striatum from Aralar-deficient mice (Fig. 6E) was not 
accompanied by any change in the GABA synthesis enzyme GAD, a more immature 
marker for GABA-containing neurons (not shown). These results suggest a deficiency 
in maturation of medium spiny GABA neurons in aralar-deficient striatum.  
  Regarding presynaptic DA terminals, the fall in VMAT2 (of about 42%) suggests that 
the vesicular storage of DA is also impaired in aralar-deficient striatum.  
 
Increased oxidative stress in aralar-KO striatum 
The increase in the DOPAC/DA ratio in Aralar-KO striatum (Table 3) indicates an 
increased intracellular oxidation of DA which would lead to an increase of H2O2 
formation via mitochondrial MAO activity (Fig. 7) which could result in a selective 
oxidative stress in DAergic neurons (Spina and Cohen, 1989). To verify this 
hypothesis, we measured the content of reduced (GSH) and oxidized glutathione 
(GSSG) in striatum and other brain regions (limbic system and brainstem) as readout 
of the cellular redox state (White et al., 1986; Spina and Cohen, 1989).  
  No changes in GSH levels were found in striatum but the content of GSSG was 
more than two-fold higher in Aralar-KO compared to WT mice (Fig. 6B). GSH and 
GSSG content in Aralar-KO mice was unchanged in the other brain regions analyzed 
(limbic system and brainstem; Fig. S2).  The decreased GSH/GSSG ratio in Aralar-
deficient striatum, suggests that this brain region is subjected to high oxidative stress 
(Fig. 6B). 
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  DISCUSSION   
Aralar-KO mice present a short lifespan, dying at PND20-22, with generalized 
tremor and motor coordination defects (Jalil et al., 2005). Now we show that Aralar-KO 
mice exhibit a marked retardation in neurodevelopment, hyper-reactivity, hyper-
activity, anxiety, motor discoordination and lack of postural control. CNS from Aralar-
KO mice have no apparent neuronal cell death but show a severe hypomyelination 
and modifications in cortical projections (Jalil et al., 2005; Sakurai et al., 2010; Ramos 
et al., 2011). In fact, KO mice showed a pronounced shutdown in the major myelin 
lipids galactocerebrosides, myelin proteins, (Jalil et al, 2005) and in mRNAs encoding 
for proteins involved in myelination (Table S1). However, the severity of the 
phenotype observed in Aralar-KO mice cannot be explained exclusively by 
hypomyelination as hypomyelination and even the absence of CNS myelin has been 
proved not to be lethal per se in mice (Wolf et al., 1999; Matalon et al., 2000).   
Aralar-KO mice show a higher exploratory activity, hyperactivity and anxious-like 
behaviour with aversive conditions as well as an increase in rearing; parameters that 
are known to be sensitive to interferences with the DAergic system (Bernardi et al., 
1981). Herein, we also observe that Aralar-KO mice have a loss in motor coordination 
and alterations in the gait pattern and equilibrium, deficits that have been extensively 
associated to striatal DAergic damage (Menéndez et al., 2006; Taylor et al., 2011). 
Failure to perform homing test, in Aralar-KO mice, constitutes a reliable indicator of 
reduced motivation associated to dopamine deficiency (Palmiter, 2008), but deficits in 
olfactory discrimination is one of the first nonmotor symptoms observed in patients with 
Parkinson and in a mice model for DAergic damage (Taylor et al., 2011). Accordingly 
to the behavior observations, KO mice (PND20) showed depletion of DA in DA 
projection-rich areas, striatum and limbic system, and DA turnover was found to be 
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highly increased in striatum. Significant increased DA turnover was also observed in 
striatum of adult (18 months-old) and healthy Aralar-hemizygote mice (Llorente-Folch 
et al., unpublished). The KO mice also showed a marked decrease in 5-HT and its 
metabolite 5-HIAA in brainstem and diencephalon, the regions with higher 5-HT levels 
in control animals. An increase in locomotion and DA turnover could be associated to 
acceleration of cellular DA uptake (Husain et al., 1994), as supported by the higher 
DAT/VMAT2 ratio found in Aralar-KO striatum as compared to controls. However, 
hyperactivity in open field might be also related to anxiety-dependent behavior, due to 
DA (Zweifel et al., 2011) and 5HT depletions (for review, Fernandez and Gaspar, 
2011), since it was only detected in novelty-related experimental situations.  
  Nigrostriatal DAergic system and striatum, seem to be preferentially vulnerable to 
Aralar-MAS deficiency in agreement with the notion that striatum is highly susceptible to 
mitochondrial dysfunctions (Pickrell et al., 2011). We report a marked enlargement in 
the lateral ventricles with a significant decrease in the size of striatum of Aralar-KO 
mice. This reduction in size might be related to an extensive lack of myelin and/or to a 
loss of neuronal projections in this region (Ramos et al., 2011). Together with these 
findings, fall in GABA (striatum was the only brain region presenting a significant 
shutdown) and a pronounced decline in Glutamate and Glutamine were found. Our 
results now reveal two new defects related to Aralar deficiency in striatum: 1) Inability of 
GABAergic striatal neurons to achieve a mature phenotype. These neurons remain 
immature as reflected by the spared DARPP32 (a protein that mediates DAergic 
neurotransmission in almost all the medium spiny neurons), with little variations in 
GABA or GAD expression; and, 2) loss of DA and DA mishandling reflected by 
increased DOPAC/DA ratio. The significant reduction in striatal VMAT2 of Aralar- KO 
mice supports that the presynaptic DAergic nerve endings are damaged but still present 
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since DAergic markers as TH and DAT were unaffected. In contrast to striatum, in 
regions enriched in DAergic somata as brainstem and diencephalon, DA content was 
found to be increased, perhaps due to an attempt to compensate for any dysfunction in 
the surviving DAergic neurons, as occurrs in the very early stages of Parkinson´s 
disease (PD) (Hefti et al., 1980; Hornykiewicz and Kish, 1987; Altar et al., 1987). 
The impairment of the dopaminergic system, particularly in the dopaminergic striatal 
terminals of the Aralar-KO mouse, is probably related, besides to its specific vulnerability 
to oxidative stress, to an increase in oxidative stress caused by the lack of Aralar-MAS 
activity. This increased oxidative stress was reflected, between others, in the very 
significant decrease in the GSH/GSSG specifically in Aralar-KO striatum. Although total 
GSH, the most abundant antioxidant in brain found to be decreased in DAergic pathology 
as PD (Sofic et al., 1992; Pearce et al., 1997; Pisani et al., 2006), was not significantly 
changed. In Aralar-KO mice, striatal GSSG, representing aprox. 1% of the total 
glutathione, was more than two-fold of control value. Because GSSG increase was 
probably localized mainly to DA nerve terminals which constitute only 1% or less of the 
mass of the striatum; this signify very much higher concentrations of GSSG within DA 
terminals of Aralar-KO striatum. The very significant decrease in the GSH/GSSG 
specifically in Aralar-KO striatum is related to increased oxidative stress (Spina and 
Cohen, 1981) in the cytosol which has the largest GSH pool and/or the mitochondria that 
contains a much smaller GSH pool (Murphy, 2011). Although we believe that the initial 
decrease in GSH is mitochondrial (see below), H2O2 escaped from mitochondria to the 
cytosol probably contributes to the decrease in cytosolic GSH/GSSG.  
Mitochondria produce O2- and H2O2 which are detoxified by thanks to GSH and 
thioredoxin together with a number of enzymes that ultimately use one of these two 
thiol molecules as redox agents (Murphy, 2011), The regeneration of the reduced 
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forms of glutathione and thioredoxin requires NADPH. There are three systems which 
produce NADPH in brain mitochondria, NADP-isocitrate dehydrogenase, malic enzyme 
and energy dependent nicotinamide nucleotide transhydrogenase (NNT) (Andres et al. 
1980; Albracht et al., 2011). The third of these systems, NNT, utilyzes mitochondrial 
NADH and the proton electrochemical gradient to produce NADPH.  There is evidence 
that NNT is important in supplying NADPH for mitochondrial detoxification, as the lack 
of NNT increased O2-/H2O2 production in mitochondria of beta cells (Freeman et al., 
2006).   
 NADPH production through NNT may be limited by mitochondrial NADH 
production. In brain, which utilizes glucose as main energy source, mitochondria 
produce NADH from pyruvate in the tricarboxylic acid cycle. The lack of Aralar results 
in a pronounced decrease in MAS, the major NADH shuttle in brain, (Jalil et al., 2005) 
resulting in an increased lactate-to-pyruvate ratio (Pardo et al., 2011), and in a 
limitation in pyruvate supply to mitochondria as reflected in a reduced maximal 
respiration rate in intact neurons (Gómez-Galán et al., 2011). This scenario is one in 
which mitochondrial NADH production is clearly limited, and this will result in a lack of 
inactivation of O2- and H2O2 which will cause oxidative damage to Aralar-KO 
mitochondria, and the escape of H2O2 to the cytosol (Han et al., 2003), causing 
oxidative stress in this cellular compartment.  
ROS formation is further potentiated in Aralar-KO striatum because VMAT2 
deficiency resulting in an increase in non-vesicular DA that might favour both MAO-
mediated oxidation and autooxidation of non-protected cytosolic DA. These two 
processes lead to the formation of ROS such as hydrogen peroxide, and reactive quinone 
and semi-quinone species produced by DA autooxidation (Graham, 1978; Maker et al., 
1981). Furthermore, DACHR (o-quinone dopaminochrome, a product of DA oxidation) 
Page 19 of 67 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 20
has been reported to increase, in a dose-dependent way, the production of H2O2 
constitutively observed at Complex I of the mitochondrial respiratory chain (Zoccarato et 
al., 2005). Our data suggest that the rate of production of ROS evoked by Aralar 
deficiency in striatum override cellular mechanisms for reducing GSSG and might have 
important consequences in the DA neuronal physiology that are more sensitive to 
oxidative stress (Drechsel and Patel, 2008; Zeevalk et al., 1997). Besides enhanced ROS 
formation, DA neurons are prone to ROS attack, i.e. the scarce proportion of glial cells 
surrounding DA neurons in the substantia nigra (for review, Mena et al., 2002), the 
presence of neuromelanin pigment in subpopulations of DA-containing mesencephalic 
neurons (Hirsch et al., 1988) and the low content of mitochondria in DA neurons of the 
substantia nigra pars compacta (Liang et al., 2007) might be mentioned between other 
characteristics.  
 Decreased VMAT2 expression was found exclusively in striatum, but not in limbic 
system, of Aralar-KO mice as a remarkable event involved in DAergic 
neurodegeneration. This fact was previously reported as a key pathogenic event 
preceding nigrostriatal dopamine neurodegeneration and clinical manifestations in a 
primate model of PD (Chen et al., 2008). These authors suggested that loss of VMAT2 
might be due to an association with α-synuclein aggregates induced by oxidative 
stress as a result of (1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine) MPTP, a DA toxin, 
treatment. Accordingly to this, previous work had proposed a direct interaction between 
VMAT2 and α-synuclein, disrupting synaptic vesicle dynamics (Lotharius and Brundin, 
2002; Mosharov et al., 2006; Guo et al., 2008; for references, Taylor et al., 2011). 
Consequently, in the Aralar-KO mice, the marked decrease in mitochondrial NADH and 
ROS detoxyfication capacity might result in oxidative stress (see Fig. 7); but, if VMAT2 
loss is related to its sequestration with alpha-synuclein aggregates remains an open 
Page 20 of 67Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21
question in our model. The mishandling of DA via reduced VMAT2, associated to an 
increased striatal DOPAC/DA (Fig. 6A), and GSSG/GSH ratios (Fig. 6B), might be 
sufficient to cause DA-mediated toxicity and neurodegeneration in the nigrostriatal DA 
system (Mooslehner et al., 2001; Caudle et al., 2007; for review, see Taylor et al., 
2011). These data point out the close relationship between Aralar-MAS activity and DA 
handling in the nigrostriatal pathway.  
 Besides the decrease in VMAT2 content, decrease in VMAT2 activity by nitration 
might be another possible mechanism involved in ROS attack (Guo et al., 2008; 
Watabe and Nakabi, 2008). It is worth also to note that the presence of VMAT2 in 
presynaptic vesicles attenuates the deleterious effect of MPTP, the most powerful toxin 
for dopaminergic neurons linked to the genesis of PD. Indeed, in VMAT2 heterozygous 
knockout mice, MPTP toxicity was twice that observed in wild-type mice (Gainetdinov 
et al., 1998); and a selective reduction in dopamine storage by VMAT2 might be a 
pathogenic feature of PD (Lee et al., 2000). 
The present results demonstrate that AGC1-MAS deficiency in mice might be 
considered as a CNS disorder targeting monoaminergic brain systems specifically 
striatum, with no apparent pathology in muscle, where Aralar is also highly expressed. 
DA neurotransmission is also altered in mice with mutations of α- synuclein, parkin or 
DJ-1, considered as suitable models for PD studies. These mice, similar to what is 
reported herein for Aralar-KO and previously for VMAT2-KO mice (Colebrooke et al., 
2006), do not display loss of midbrain DA neurons, the hallmark of Parkinson’s disease 
(Dawson et al., 2010, for references). It is worth to take into account that mice possess 
low neuromelanin and high GSH content what might render them specially resistant to 
DA degeneration compared to primates and humans. These factors would contribute to 
underestimate the detrimental effects of Aralar-MAS deficiency on the DA system in 
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humans. Deficiencies or failure in the operation of the Aralar-MAS pathway, resulting in 
a limited mitochondrial NADH formation and ROS detoxyfing capacity, might constitute 
an important factor at the origin of DA degeneration and its implication in human 
pathologies as Parkinson´s and Huntington´s diseases might be thoughtfully explored. 
Novel therapeutics in human to optimize Aralar-MAS shuttle function in brain might 
improve healthy physiology of DA neurons and/or prevent them from degeneration. 
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Aminoacids Striatum Diencephalon Limbic system Brain stem Cer. Cortex Cerebellum
(nmol/g tissue)
Aspartate Aralar WT 2264 ± 175 2466 ± 122  1894 ± 232  2409 ± 156 2356 ± 91  2379 ± 62  
Aralar KO 454 ± 41 *** 429 ± 21 *** 399 ± 48 ** 562 ± 34 *** 430 ± 54 *** 706 ± 61 ***
(%vs WT) 20% 17% 21% 23% 18% 29%
Serine Aralar WT 1101 ± 90  790 ± 74    1014 ± 159    514 ± 19   1000 ± 33   709 ± 48    
Aralar KO 160 ± 16 *** 164 ± 13 ** 138 ± 9 ** 168 ± 26 *** 196 ± 24 *** 215 ± 18 **
(%vs WT) 14% 21% 13.6% 33% 20% 30%
Alanine Aralar WT 783 ± 97   573 ± 39     870 ± 128    525 ± 18   805 ± 22     497 ± 19   
Aralar KO 297 ± 63 ** 180 ± 18 *** 211 ± 15 ** 238 ± 36 *** 261 ± 23 *** 201 ± 19 ***
(%vs WT) 38% 31% 24% 45% 32% 40%
Glutamate Aralar WT 7512 ± 487 7615 ± 321 8166 ± 1076 5840 ± 258 8326 ± 252 8071 ± 237
Aralar KO 4030 ± 238 ** 3935 ± 230 *** 4446 ± 577 ** 4141 ± 235 ** 5797 ± 575 ** 5202 ± 418 ***
(%vs WT) 54% 52% 54.4% 71% 70% 64%
Glutamine Aralar WT 3019 ± 258  2880 ± 143 2548 ± 301 2653 ± 205 2449 ± 231 3808 ± 143 
Aralar KO 895 ± 166 *** 1387 ± 233 ** 1133 ± 268 ** 2569 ± 185 1471 ± 264 ** 3119 ± 352 *
(%vs WT) 29% 48% 44.4% 97% 60% 82%
GABA Aralar WT 2523 ± 260   2563 ± 237 1568 ± 221 1543 ± 133 1558 ± 68   1442 ± 103 
Aralar KO 1512 ± 141 **                     2682 ± 116 1223 ± 159 1979 ± 194 * 1863 ± 88 ** 1062 ± 93
(%vs WT) 60% 105% 77% 128% 119% 74%
Table 1.  Amino acid content in brain extracts from Aralar WT and Aralar KO mice 
at 20 days (striatum, diencephalon, hipocampus, brain stem, cerebral cortex, and 
cerebellum).  
cv 
Results are expresssed in nmol per gr of tissue. Values are the mean ± s.e.m. (n=3-6). 
Statistical analysis was performed by one-way analysis of variance followed by Student-
Newman-Keuls t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001 Aralar KO versus Aralar 
WT mice. 
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Table 2- Monoamine metabolism in striatum, diencephalon, limbic system and 
brainstem of Aralar WT and Aralar KO mice. 
 
Results are expresssed in nmol per gr of tissue. Values are the mean ± s.e.m. (n=6). 
Statistical analysis was performed by one-way analysis of variance followed by 
Student-Newman-Keuls t-test. * p < 0.05, ** p < 0.01,  *** p < 0.001 Aralar KO versus 
Aralar WT mice. 
 
 
Monoamines Striatum Diencephalon Limbic system Brain stem
(nmol/g tissue)
DA Aralar WT 5690 ± 525 341 ± 92  1412 ± 220  97.7 ± 18 
Aralar KO 3661 ± 175 ** 431 ± 88 810 ± 82 * 164 ± 51
(%vs WT) 64% 126% 57% 168%
3-MT Aralar WT 330 ± 39 n.d ≤ 6    59.7 ± 6.2    n.d ≤ 6    
Aralar KO 142 ± 29 ** n.d ≤ 6    n.d ≤ 6    n.d ≤ 6    
(%vs WT) 43%
DOPAC Aralar WT 387 ± 10   84 ± 10     141 ± 14    43.8 ± 2.7   
Aralar KO 362 ± 38 127 ± 10 * 71 ± 17 ** 73.7 ± 8 **
(%vs WT) 93% 151% 50% 168%
HVA Aralar WT 681 ± 35 219 ± 21 136.5 ± 12.1 61.6 ± 6.4 
Aralar KO 468 ± 64 * 279 ± 18 115.2 ± 6.6 85.2 ± 7.5 *
(%vs WT) 68% 127% 85% 138%
NA Aralar WT 251 ± 20  846 ± 22 336 ± 20 1223 ± 60 
Aralar KO 265 ± 30 1008 ± 98 320 ± 28.8 1359 ± 36.5 
(%vs WT) 105% 119% 95% 111%
5-HT Aralar WT 333 ± 67   1501 ± 242 585 ± 55 1988 ± 39 
Aralar KO 250 ± 89                     768 ± 88 * 460 ± 58 1445 ± 172 *
(%vs WT) 75% 51% 79% 72%
5-HIAA Aralar WT 256 ± 102  859 ± 95 337 ± 40 484 ± 16  
Aralar KO 99 ± 28 375 ± 42 *** 218 ± 29.5* 285 ± 25 ***
(%vs WT) 38% 43% 64% 59%
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Table 3- Turnover of monoaminergic neurons measured in brain regions (striatum, 
diencephalon, limbic system and brain stem) of Aralar WT and Aralar KO mice. 
 
Values are the mean ± s.e.m. (n=6). Statistical analysis was performed by one-way 
analysis of variance followed by Student-Newman-Keuls t-test. * p < 0.05 Aralar KO 
versus Aralar WT mice. 
 
 
 
 
 
 
 
 
 
Ratios Striatum Diencephalon Limbic system Brain stem
(nmol/g tissue)
DOPAC/DA x 102 Aralar WT 7.1 ± 0.7 28.4 ± 3.0 11.7 ± 2.1 50.6 ± 7.0
Aralar KO 9.9 ± 1.0 * 33.8 ± 5.3 8.7 ± 1.7 55.7 ± 7.8
(%vs WT) 138% 119% 78% 110%
HVA/DA x 102 Aralar WT   12.6 ± 1.5   76.2 ± 10.3 11.4 ± 2.0 5.6 ± 10.0
Aralar KO 12.7 ± 1.5  74.0 ± 10.6 15.3 ± 2.0 * 73.7 ± 6.7
(%vs WT) 101% 97% 134% 97%
DOPAC/HVA x 102 Aralar WT 57.7 ± 3.0 38.8 ± 3.1 209.0 ± 15.2 67.6 ± 6.9
Aralar KO 79.7 ± 4 * 45.6 ± 1.1 131.6 ± 35.2 73.9 ±5.6
(%vs WT) 138% 117% 63% 109%
5HIAA/5HT x 102 Aralar WT 75.1 ± 16.8 65.3 ± 14.6      58.0 ± 4.0 24.4 ± 0.9
Aralar KO 55.8 ± 11.3 49.6 ± 3.2 50.2 ± 6.8 20.8 ± 2.3
(%vs WT) 74% 76% 86% 85%
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Legend to Figures: 
 
Figure 1- Neurobehavioral development is strongly affected in Aralar-KO mice. Toe pinch 
and reaching response at PND17 (A). Quantitation of seizures during postnatal 
development (B). Touch escape (C) and homing test (D, denoting exploratory, social and 
motor behaviour) are illustrated in wild-type (open circles or bars), Aralar-hemizygote (grey 
circles or bars) and Aralar-KO mice (filled circles or bars). Data are expressed as the 
mean ± s.e.m (n= 8-13 mice per group). .* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 2- Openfield studies show high levels of hyperactivity and anxiety in Aralar-KO 
mice. Parameters as total travelled distance (A), mean speed of walk (B) and resting time 
between displacements (C) in the center and periphery of the arena and at dark (basal)-
light (aversive) conditions are valutated in WT, Aralar-hemizygote and Aralar-KO mice. 
Data are expressed as the mean ± s.e.m (n=8-13 mice per group). * p ≤ 0.05, ** p ≤ 0.01. 
 
Figure 3- Aralar-KO mice showed a marked improvement in postural control, delayed 
neurodevelopment and lack of equilibrium. Surface righting response (A), wire suspension 
(B), negative geotaxis (C), and latency from pivoting to alking (D) were studied at 
indicated PNDs in wild-type (open circles or bars), Aralar-hemizygote (grey circles or bars) 
and Aralar-KO mice (filled circles or bars).  Data are expressed as the mean ± s.e.m (n = 
8-13 mice per group). .* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 4- Aralar-KO mice have a dramatic motor discoordination. In the pawprinting test 
(A, B) it is noticeable that Aralar-KO mice have a shorter stride length and a shorter 
hindpaw length than the WT siblings (A), and an erratic direction of walk (B). Asymetric 
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gait at the right leg is shown in the footprint left by the hind limbs of Aralar-KO mice 
walking on the paper (B).  The beam balance test (C) was performed in wild-type (open 
circles), Aralar-hemizygote (grey circles) and Aralar-KO mice (filled circles). 1 and 2- 
indicates the number of assay. (n=10-13 mice per group).  
 
Figure 5- Aralar-KO mice show no morphological abnormalities in brain, with an 
enlargement in lateral ventricule and a reduction in size of striatum as compared to their 
WT siblings. View of coronal sections are shown stained with cresyl violet in wild-type (wt) 
and Aralar-KO animals at PND20 (scale bar, 500 µm) (A). (B) Quantitation of the area for 
striatum and hippocampus versus that of whole brain is represented, as percentage, in 
Aralar-WT (open bars) and Aralar-KO mice (filled bars; n= 4). (C) View of coronal sections 
of the brain from WT and Aralar-KO mice at PND20 as observed at the high power (scale 
bar, 500 µm). Data are expressed as the mean ± s.e.m (n = 6 mice). (D) The number of 
positive-neurons for TH in the substantia nigra (SN) and midbrain was found to be equal in 
Aralar-KO as compared to control mice. * p ≤ 0.05. 
 
Figure 6- Striatum appeared to be the most affected region in Aralar-deficient brain. (A) 
Differential effects of Aralar deficiency on DA metabolism in brain regions enriched in DA 
terminals (striatum and limbic system). DA and its metabolites, except DOPAC, are 
significantly decreased in Aralar-KO striatum. DA turnover is increased in Aralar-KO 
striatum. (B) The enhanced striatal DA turnover provoked an increase in cellular oxidative 
stress as measured by GSH/GSSG ratios. (C) Scheme of tyrosine metabolism into the 
presynaptic and postsynaptic neurons in striatum, representing metabolites, enzymes and 
proteins involved (D-F) Expression of dopamine markers in Aralar-KO striatum and limbic 
system. Representative Western blot of TH, DAT in striatum (D); and VMAT2, DARPP32 
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proteins in striatum (E) and limbic system (F) with their respective densitometric 
histograms. β-actin was used as charge control. Results are expressed as the mean ± 
s.e.m (n = 6 mice per group). Statistical analysis was performed by one-way ANOVA 
followed by Newman–Keuls test.* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 7- Mechanism for toxicity induced by the lack of Aralar in DAergic nigrostriatal 
nerve terminals. Lack of Aralar-MAS activity causes a decrease in mitochondrial 
NADH because both lack of redox transfer by the shuttle and limited pyruvate supply 
to mitochondria; and also decreased mitochondrial NAD(P)H content. Since 
glutathione system (and thioredoxin) for ROS detoxification is reduced by the 
mitochondrial NADPH pool; increased ROS is expected to happen in Aralar-deficient 
mitochondria. Mitochondrial ROS (O2- and H2O2) diffuse to the cytosol, provoking 
increased levels of cytosolic alpha-synuclein aggregates and synuclein-VMAT2 
complexes in the presynaptic DA nerve terminals of Aralar-KO mice, with loss of 
VMAT2. Consequently, an increase in cytosolic DA produces an enhancement in DA 
autoxidation and in enzymatic oxidation via MAO activity (with higher DOPAC/DA 
ratio). Both pathways involve an overproduction of ROS, as reflected by increased 
GSSG, in Aralar-KO striatum. This further potentiates VMAT2 decline and possibly 
loss-of-function in the DA terminal with the subsequent mishandling of DA. AGC, 
aspartate-glutamate carrier; Asp, aspartate; AAT, aspartate aminotransferase; DA, 
dopamine; DOPAC, 3,4-dihydroxy-phenylacetic acid; G6P, glucose 6 phosphate; Glu, 
glutamate; Gluc, glucose; GA3P, glyceraldehyde 3-phosphate; GPx, glutathione 
peroxidase; GR, glutathione reductase; GSH, reduced glutathione ; GSSG, oxidized 
glutathione; α-KG; α-ketoglutarate; Lac, lactate; Mal, malate; MAO, monoamine 
oxidase; MDH, malate dehydrogenase; NNT, NADH-NADP-transhydrogenase; OAA, 
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oxalacetic acid; OGC, α-ketoglutarate-malate carrier; Pyr, pyruvate;  VMAT2, 
vesicular monoamine transporter 2. 
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SUPPLEMENTARY INFORMATION 
 
“AGC1-malate aspartate shuttle activity is critical for dopamine 
handling in the nigrostriatal pathway” 
 
Irene Llorente-Folch1, Ignasi Sahún2, Laura Contreras1, María José Casarejos3, Josep 
María Grau4, Takeyori Saheki5, María Angeles Mena3, Jorgina Satrústegui1, Mara 
Dierssen2, and Beatriz Pardo*1 
 
MATERIALS AND METHODS 
 Animals 
Male SVJ129 x C57BL6 mice carrying a deficiency for ARALAR expression (Aralar 
wild-type, WT; Aralar heterozygous, HT; and Aralar Knock-out, KO) were obtained 
from Lexicon Pharmaceuticals, Inc. (The Woodlands, TX, USA) (1). The mice were 
housed in a humidity- and temperature-controlled room on a 12-h light/dark cycle, 
receiving water and food ad libitum. Genotype was determined by PCR using genomic 
DNA obtained from tail or embryonic tissue samples (Nucleospin tissue kit, Macherey-
Nagel) as described previously (Jalil et al., 2005). All the experimental protocols used 
in this study were approved by the local Ethics Committees at the Center of Molecular 
Biology “Severo Ochoa”, Autónoma University (UAM), Madrid, and at the Center for 
Genomic Regulation, Barcelona. 
 
 General procedure for postnatal observations. 
All the pregnant females were allowed to deliver spontaneously. Each pup was 
checked for gross abnormalities and the day after delivery was designated as PND1 of 
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age for neonates (estimation error on time of birth ± 8h). The pups were individually 
marked with ink and were nursed by their natural dams until weaning. During the 
testing protocol whole litters were separated from the dam less that 10 min and 
maintained in a warm environment. Males and females were pooled to perform the 
neurodevelopmental screening. All the measures were performed between 5:00 a.m 
and 8:00 a.m. All experiments procedures were approved by the Animal Care 
Committee of the Centre for Genomic Regulation. For the developmental screening 42 
animals, males and females, were employed from five different litters. 
 
 Assessment of body growth 
The pups were weighted daily from PND1 to PND5 and then every two days. The 
length of the body from the tip of the nose to the base of the tail and the length of the 
tail were recorded after determining the weight of the animals.   
 
 Developmental landmarks 
The unit of analysis was the day of attainment of the criterion for each landmark. A 
brief description of each measure was as follows: 1) Pinna detachment: Pups were 
inspected for the complete separation of the pinna from the cranium from PND3. 2) 
Incisor eruption: Beginning on PND7, pups were inspected for the emergence of both 
lower and upper incisor from the gingiva. 3) Eye opening: Beginning on PND11, pups 
were inspected for the complete opening of both eyelids. 4) Permeation of ear 
conduct: Pups were inspected for opening of the auditory conduct. 
 
 Neurobehavioral development 
 Reflex and Sensory Function  
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Visual Placing: After the opening of the eyes, the pup was suspended by the tail 
and lowered towards the tip of a pencil without the vibrissae touching it, on PND17. 
The response was considered to be positive when the paws were extended to touch it. 
Blast response:  Exaggerated jumping or running behaviour in response to a gentle 
puff of air, on PND11.  
Tactile Orientation: The test assessed the head turning (orienting) response triggered 
by the application to one side of the perioral area a cotton Q-tip, beginning on PND11. 
Vibrissae Orientation: The pups were suspended by the tail and lowered towards the 
tip of a cotton Q-tip. At contact of the cotton with the vibrissae, the pup raised its head 
and performed a placing response, beginning on PND8. 
Preyer reflex/Startle response: The response of the pups to a moderate sound burst 
consisting of a moderately brink flick of the pinna or startle response was recorded, 
beginning on PND11. 
Toe Pinch: The test assessed the presence or absence of withdrawal answer against 
a mild painful stimulus, exerting pressure in a hind paw with the fingers, on PND17.  
Reaching Response: The animal is held by the tail above a flat surface and it is noted 
if the forepaws are stretched out to make contact with th  surface, on PND17.  
Touch escape: Response of the animal to a finger stroke from above was recorded 
and scored, beginning on PND13, as follow: 0= no response, 1= moderate (rapid 
response to light stroke); and 2= vigorous (escape response to approach). 
Convulsions: Spontaneous convulsions were recorded and scored as: 0= no 
convulsion, 1= moderate convulsion, 2= strong convulsion, in a longitudinal evaluation 
from PND3 onwards. 
 
Neonatal Reflex and Acquisition 
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Root: After bilateral stimulation of the body, the pup was crawled forwards, pushing 
the head in a rooting fashion. We analyse the extinction of this archaic reflex from 
PND4 to PND8. 
Crossed Extensor: When pinched, the stimulated limb flexed while the opposite limb 
extended. We analyse the extinction of this archaic reflex, from the very beginning to 
onwards. 
Forepaw/Hindpaw Grasping: It was considered positive when the pup flexed the paw 
to grasp an object that was gently stroking it. The day of appearance of the reflex was 
recorded, starting on PND2. 
Forpaw/Hindpaw Placing: When the dorsum of the paw or foot contact with the edge 
of an object, the hand or foot lifted and was placed on the object. It was recorded from 
PND4 to PND15. 
 
Neuromotor Development 
Surface righting response: The pup was placed on its back and the latency to turn 
over to rest in the prone position with all four feet on the floor was recorded (cut-off 
time 30 sec) starting the performance on PND4 until PND11. 
Negative geotaxis test: The pups were placed head downward on a 45º incline and 
the latency to turn 180º was recorded, with a maximum latency of 30 sec, beginning 
on PND4 to PND15. 
Wire suspension: The animals were forced to grasp a 3 mm-tick wire and hang from it 
on their forepaws. The ability of the animals to grasp the wire was scored and the time 
they held on the wire (maximum 30 sec) was registered. It was performed in PND13, 
15 and 17 and latency to fall was correlated with the weight of the animal.  
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Walking/Pivoting: The latency for a mouse to lift up on all four paws and walk a 
distance exceeding its body length was measured on a flat surface covered with a 
paper, on PND8 and PND13. 
 Pivoting locomotion: The total number of degrees turned by the pup during a 60 sec 
period was recorded. The test was performed on a flat surface covered with a paper 
on which lines had been drawn to delineate four 90º quadrants. The number of 
degrees was scored only in completed 90º segments.  
 
 Homing Test 
 On PND19 individual pups were transferred to a cage containing new sawdust with 
a bite portion of sawdust of the home litter “goal arena”. The pups were located at the 
opposite side of the goal arena, near to the wall. The time taken to reach the home 
litter sawdust was recorded (cut-off time 60 sec). 
 
Paw Print test 
To examine the step patterns of the hind limbs during forward locomotion, mice 
were required to traverse a straight, narrow tunnel. Th  experiments to evaluate the 
walking pattern of the mice were adapted from previous work by Martínez de Lagrán 
et al. (2004) and performed on PND18. The hind paws of the pups were coated with 
blue nontoxic waterproof ink. Animals were then placed at one end of a long narrow 
tunnel (10 X 10 x 30 cm), and in the opposite end there were placed part of their nest. 
They spontaneously enter and partially or totally traverse the tunnel. A clean sheet of 
white paper was placed on the floor of the tunnel to record the paw prints. The pattern 
of three consecutive steps (the first four steps were excluded from the analysis) was 
analysed and the following parameters assessed, averaged over consecutive steps: 
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(1) stride length, the averaged distance between each stride; (2) hindpaw base width, 
measured as the average distance between left and right hind footprint overlap. These 
values were determined by measuring the perpendicular distance of a given step to a 
line connecting its opposite preceding and proceeding.  
  
 Beam balance test 
On PND19 individual pups were located in a trip of 40 X 2 cm elevated 25 cm from 
the surface. They began the task in the middle of the wooden trip and they should 
travel to reach the end of the trip with a cut-off time of 60 sec. Latency to the first 
movement, arrival latency and latency to fall were recorded. There was a first training 
session where the animals performed the task and learned about the mechanism. 
Mice were guided along the trip holding them by the tail to avoid any fall if they were 
not able to do it themselves. In a period of an hour the test was repeated, in this case 
without any help and counting the times.  
 
Open field test   
The open field was a white melamine box (70 × 70 × 50 cm high) divided into 25 
equal squares and under high intensity light levels (high-lightening, 500 Lux) or in 
darkness (low-lightening, with weak red light). Mice tend to avoid brightly illuminated, 
novel, open spaces, so the open field environment acts as an anxiogenic stimulus and 
allows for measurement of anxiety-induced locomotor activity and exploratory 
behaviours. Thus, two zones, centre (1764 cm2) and periphery (3136 cm2) were 
delineated, being the centre more anxiogenic. At the beginning of the test session, 
mice at PND15-16 were left in the periphery of the apparatus and during 5 min we 
measured and analysed the latency to cross from the periphery to the centre, total 
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distance travelled, average speed and time spent in several sectors of the field (i.e. 
the border areas versus the open, central area). Observation was made in an 
actimeter (Panlab, Barcelona) by computerized analysis of movements. 
 
Measurements of glutathione in brain regions 
Total glutathione (Gsx) levels were measured by the method of Tietze (1969). A 
sample (40 μl) of the sonicated brain region supernatant in 0.4 N PCA was neutralized 
with four volumes of phosphate buffer (0.2 M NaH2PO4, 0.2 M Na2HPO4, 0.5 M EDTA, 
and pH 7.5). Fifty microlitres of this preparation were mixed with DTNB (0.6 mM), 
NADPH (0.2 mM) and glutathione reductase (1 unit) and the reaction was monitored in a 
P96 automatic microtiter reader at 412 nm for 6 min. Oxidized glutathione (GSSG) was 
measured as described by Griffith (1980). After the neutralization with the phosphate 
buffer, the sample remaining was mixed with 2-vinylpyridine (1.2 μl) at RT for 1 h and the 
reaction was carried out as described earlier. Reduced glutathione (GSH) was obtained 
by substracting GSSG levels from Gsx levels. 
 
 Histological  and immunohistochemical studies in brain. 
 Animals were anesthetized by chloral hydrate (0.5 mg/g body weight; Sigma-
Aldrich) and transcardially perfused with saline buffer (0.9% NaCl in phosphate 
buffer) and then with 4% formaldehyde in phosphate buffer (formalin fixative). Brains 
were carefully removed and postfixed overnight in formalin (4 ºC) and transferred into 
sucrose (30% in phosphate buffer). Later, they were embedded in OCT compound 
(Tissue-Tek ®, Sakura Finetek Europe B. V., Zoeterwoude, NL), frozen on dry ice and 
cut into 12 series of 30 microns coronal sections with a cryotome (free floating 
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sections). Sections were kept in cryoprotectant medium (25 % glycerol, 25 % 
ethylene glycol in 50 mM phosphate buffer) and stored at -20 ºC until processing.  
 
For immunohistochemistry, sections were abundantly washed (1X PBS) and treated 
with NaBH4 (1 mg/ml in PBS pH 8.0) to quench endogenous autofluorescence. 
Endogenous peroxidase was quenched in 3% H2O2 in 10% methanol in PBS for 
20min, free-floating sections were blocked for 1h in PBS containing 10% normal horse 
serum, 0.25% Triton X-100 and incubated O/N at 4°C with antibodies against Tyrosine 
Hydroxilase (TH) (1:5000, polyclonal antibody, Millipore). Afterwards, sections were 
rinsed three times in PBS containing 0.25% Triton X-100 and then incubated for 2h 
with the secondary biotinylated antibody (goat-anti-rabbit, Vector, 1:150), followed by a 
1h reaction with avidin-biotin peroxidase complexes (regular ABC kit Vectastain, 
Vector). After a profused wash with PBS containing 0.25% Triton X-100, sections were 
then developed using 0.05% 3,3-diaminobenzidine (Sigma) as a chromogen in the 
presence of 0.03% H2O2 in PBS and 8% NiCl for 2-10min. Sections were mounted 
onto poly-Lysine-coated slides, dehydrated, and coverslipped with DPX.  
 
Cresyl Violet Immunostaining.   
Cresyl Violet is a stain used for highlighting acidic components of tissue, called Nissl 
bodies in the neuronal cell; this is useful for determining structure in the cell. Sections 
(30 µm thick) were mounted on poly-Lysine covered slides and air dried at RT for 
several days. The staining procedure consists on sequentially dipping the slides in 
different solutions starting with absolute chloroform used as an organic lipid solvent for 
30 min and continuing with 25% ethanol for 2min. Then, sections were submerged in 
stain (0.25% cresyl violet in 25% ethanol) for 5 min and subsequently in a series of 
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decreasing alcohol baths, 50% ethanol (30 sec) and 70% ethanol (5 min),  dehydrating 
the samples.  After 1 min in differentiation solution (70% ethanol, 10 drops of acetic 
acid), slides were soaked in 95% ethanol and finally in absolute ethanol for 1 min. 
Immunostaining was finished with 100% Xilene for 2 min and coverslipped with DPX 
mounting media letting them dry overnight. 
 
Histomorphological studies of muscle 
Muscle samples were frozen in cooled isopentane (liquid N2) immediately after 
their obtaining. They were stored at -80ºC until sectioning in cryostat at -30ºC at 8-10 
microns. The following histochemical reactions were performed: Hematoxilyn and 
eosin, (H&E), modified Gomori’s trichrome for frozen tissue (TCR), non-specific 
esterase (NEE), Oil-red O, (ORO), NADH- tetrazolium reductase (NADH-TR), and 
ATP-ase at pH 9.4. The whole protocol for each reaction was that used in routine 
analysis of human muscle pathology and can be obtained elsewhere (Dubowitz and 
Sewry , 2007). Muscle biopsies were processed by an expert and blinded muscle 
pathologist (JMG).  
 
Statistical analysis 
For behavioral and motor tests, variance homogeneity and normality of data were 
tested by means of Levene and Shapiro–Wilk tests, respectively. Simple comparisons 
between genotypes mice were performed using the two-tailed unpaired Student´s t test 
with Whitney’s correction to account for the different variances in the populations being 
studied. If the data did not meet specifications required for parametric analysis, non-
parametric analysis of variance was used (Kruskal-Wallis) followed by comparisons 
between groups (Mann-Whitney U). Data were expressed as mean F SEM. In all tests, 
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a difference was considered to be significant if the obtained probability value was P < 
0.05. These statistical analyses were performed with a commercial software package 
(Statistica 7.0). 
 
Sample labeling and microarray hybridization 
RNA purification 
Mice (PND15) were sacrificed by cervical dislocation and brains were quickly 
extracted and frozen in liquid nitrogen. Total RNA was extracted using the RNeasy 
Tissue Kit (Quiagen), according to the manufacturer’s instructions. RNA quantity was 
assessed using the NanoDrop-1000 (NanoDrop Technologies, Wilmington, DE), and 
RNA integrity was assessed by formaldehyde agarose gel electrophoresis. Samples 
with a discrete ribosomal 28S and 18S RNA bands and a 28S/18S intensity ratio of 
>2, and with a A260/A280 between 1.8-2.1 were used for amplification and labeling for 
microarray chip hybridization. Three independent RNA samples for each genotype 
were prepared and littermate pairs of  Aralar-WT and Aralar-KO brains were 
processed and analyzed in parallel.  
 
RNA amplification and labelling 
One-Colour Microarray-Based Gene Expression Analysis Protocol (Agilent 
Technologies, Palo Alto, CA, USA) was used to amplify and label RNA. Briefly, 800 ng 
of total RNA was reverse transcribed using T7 promoter Primer and MMLV-RT. Then 
cDNA was converted to aRNA using T7 RNA polymerase, which simultaneously 
amplifies target material and incorporates cyanine 3-labeled CTP. 
 
Hybridization protocol 
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Samples were hybridized to Whole Mouse Genome Microarray 4 x 44K (G4122F, 
Agilent Technologies). 1.65 μg of Cy3 labelled aRNA were hybridized for 17 hours at 
65ºC in a hybridization oven (G2545A, Agilent) set to 10 rpm in a final concentration of 
1X GEx Hybridization Buffer HI-RPM, according to manufacturer's instructions (One-
Color Microarray-Based Gene Expression Analysis, Agilent Technologies). 
 
Washing protocol 
Arrays were washed according to manufacturer's instructions (One-Color Microarray-
Based Gene Expression Analysis, Agilent Technologies). Arrays were dried out using 
a centrifuge. 
 
Scan protocol 
Arrays were scanned at 5μm resolution on an Agilent DNA Microarray Scanner 
(G2565BA, Agilent Technologies) using the default settings for 4x44k format one-
colour arrays. 
 
Image analysis 
Images provided by the scanner were analyzed using Feature Extraction software 
(Agilent Technologies). 
 
Data Analysis 
Data files from Feature Extraction were imported into GeneSpring® GX software 
version 9.0. (Agilent Technologies). Quantile normalization was performed and 
expression values (log2 transformed) were obtained for each probe. Probes were also 
flagged (Present, Marginal, Absent) using GeneSpring® default settings. Probes with 
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signal values above the lower percentile (20th) and flagged as Present or Marginal in 
100% of replicates in at least one out of the two conditions under study, were selected 
for further analysis (25517 probes). 
In the next step, significance analysis of microarrays (SAM) (1) was used to identify 
differences in gene expression. Significance analysis of microarrays defines 
significance with the q value, an adjusted probability value for multiple comparisons. 
Statistical analysis of differential gene expression between KO and Wt (Control) was 
assessed using two-class paired SAM. 
 
Ingenuity Pathway Analysis 
Network, functional and pathway analyses of specific gene datasets were generated 
through the use of Ingenuity Pathway Analysis (Ingenuity Systems®, 
www.ingenuity.com). 
The Functional analysis identified the functions and/or diseases that were most 
significant to the dataset. Genes from the dataset that were associated with biological 
functions and/or diseases in the Ingenuity knowledge base were considered for the 
analysis. Fischer’s exact test was used to calculat  a p-value determining the 
probability that each biological function and/or disease assigned to the data set is due 
to chance alone. 
Canonical Pathway analysis identified the pathways from the Ingenuity Pathway 
Analysis library of canonical pathways that were more significant to the dataset. 
Genes associated with a canonical pathway in the Ingenuity knowledge base were 
considered for the analysis. The significance of the association between the dataset 
and the canonical pathway was measured in two ways: 1) A ratio of the number of 
genes from the dataset that map to the pathway divided by the total number of 
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molecules that exist in the canonical pathway is displayed. 2) Fisher’s exact test was 
used to calculate a p-value determining the probability that the association between 
the genes in the dataset and the canonical pathway is explained by chance alone. 
 
 
RESULTS 
 
General development, neurodevelopment and psychomotor state is altered in 
Aralar-KO mice 
 Previously, we reported a significant growth retardation with premature death 
around PND21 Aralar-KO mice (1). Herein, a battery of neurodevelopmental, 
behavioral and motor tests were carried out to elucidate the specific problems related 
to AGC1-MAS deficiency, with special attention to motor deficits since an abnormal 
gait pattern was observed in Aralar-KO mice.  
Aralar-KO mice have a reduced body and tail length from PND3, and a marked 
lower weight from PND5, never reaching normal growth compared to wild-type (WT) 
littermates (data not shown). In addition to their reduced size, Aralar-deficient mice 
suffer a delayed in the appearance of some developmental landmarks, incisor 
eruption, eyelid opening, permeation of the auditory conduct, and the functional 
measure associated with ear opening, the Preyer´s reflex (not shown). Acquisition of 
specific reflexes, such as hindpaw grasping and forepaw placing reflexes and 
extinction of archaic reflexes (rooting response and crossing extensor reflex) were 
also significantly delayed (not shown). Thus, although some phenotypic 
characteristics like pinna detachment and coat appearance occurred at the same time 
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than in WT mice, a general developmental delay was clearly present in Aralar-KO 
mice.  
When performing the toe pinch test, Aralar-KO mice presented hyper-reactivity 
as compared to WT mice (Fig. 1A), but no alteration in the sensory tests was 
observed. The lack of Aralar caused a strong impairment in the reaching response 
capacity (Fig. 1A) in no case the forepaws were stretched out to make contact with 
the surface staying all the time in curling position. Aralar-KO animals showed a limb 
clasping phenotype, instead of showing a normal escape posture. This phenotype 
along with ataxia indicates severe alterations in the neurodevelopment possibly 
compromising cerebello-cortico-reticular and/or cortico-striato-pallido-reticular 
pathways (Takahaski et al., 2010; Lalonde and Straziele, 2011).   
Spontaneous convulsions were observed in both WT and Aralar-KO mice at very 
early stages of development (from PND3; Fig. 1B), which gradually disappeared until 
complete extinction at PND15 in WT. However, in Aralar-KO mice, these convulsions 
neither disappeared nor decreased in intensity or frequency during development. 
Hyper-reactivity could also explain the results obtained in the touch escape test (Fig. 
1C), where KO mice showed an exacerbated response to a finger stroke from above 
with no aversive effect in Aralar-WT or Aralar heterozygous (HT) mice.  
 
No muscle affectation  in Aralar-KO mice 
Aralar is highly expressed in skeletal muscle (Jalil et al., 2005) and its lack 
provokes motor disabilities in mice; thus, we have also studied the consequences of 
Aralar deficiency in skeletal muscle (Fig. S1A, S1B) No differences in fibre size were 
observed (H&E, data not shown) and TCR staining did not reveal myocytolysis, 
vacuolation or the presence of macrophages (Fig. S1A). In addition type I (oxidative) 
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and type II (glycolytic) muscle fibres, detected by NADH-TR method, were present in 
similar proportions in both groups of animals (Fig. S1B). ATPase activity (by 
histochemistry) was also detected in both genotypes, although with less intensity for 
Aralar-KO (not shown). In conclusion, no histomorphological abnormalities or signs of 
pathology were detected in the gastronemius muscle of Aralar-KO mice at PND20. 
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Legend to Figure: 
 
Figure S1- (A-B) Representative images of muscle sections obtained from gastronemius 
of Aralar-KO and WT mice at 20 PND stained with TCR (A) and NADH-TR (B). 
Histomorphology revealed by these techniques show no remarkable differences between 
genotypes. (n=4). Scale bar, 40 μm.  
 
Figure S2- The content of GSH and GSSG was not significantly different in limbic sytem 
(A) and brainstem (B) of Aralar KO mice as compared to Aralar WT.  GSH/GSSG ratios 
were unchanged between genotypes in both regions (A and B). Results are expressed as 
the mean ± s.e.m (n = 6 mice per group).  
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Table S1-Enzymes with a significant 2-fold increase or reeduction in the Aralar-KO mouse 
Name Ratio (KO/WT) q-value Description Pathway Disease 
GAMT 0.49448546 0.01301 guanidinoacetate N-methyltransferase Aminoacid metabolism: Arginine, proline, serine, glycine and threonine  
MAOB 0.51619927 0.01787 monoamine oxidase B 
Catecholamine catabolism, aminoacid 
metabolism (Arg, Pro, Ser, gly, Thre, Trp, 
Tyr) 
 
PRODH  0.47565914 0.01787 proline dehydrogenase (oxidase) 1 Arg, Pro mtb. hyperprolinemia and neurological disorder. 
SDS 0.33868124 <0.005 serine dehydratase Ser, gly, Thr, Trp mtb, Lys degradation  
CYP4F8 0.35527301 0.00659 cytochrome P450, family 4, subfamily F, polypeptide 8 Trp mtb,  Arachidonic acid mtb.  
DCT 0.41151017 0.00659 
dopachrome tautomerase (dopachrome 
delta-isomerase, tyrosine-related protein 
2) 
Tyr mtb  
AASS 0.39639207 <0.005 aminoadipate-semialdehyde synthase Lys degradation  
ALOX5 0.48632747 0.00689 arachidonate 5-lipoxygenase Arachidonic acid mtb  
PLA2G4A 0.46878555 0.01301 phospholipase A2, group IVA (cytosolic, calcium-dependent) Arachidonic acid mtb neurological disorder 
PROCA1 2.24388696 0.01567 proline-rich cyclin A1-interacting protein Arachidonic acid mtb  
ACSS2 0.65022007 0.0415 acyl-CoA synthetase short-chain family member 2 glutathione mtb  
GPX6 0.56840849 0.04059 glutathione peroxidase 6 (olfactory) glutathione mtb  
GSTM1  1.98894034 0.04059 glutathione S-transferase, mu 1 glutathione mtb  
LNPEP 0.54676773 0.00659 leucyl/cystinyl aminopeptidase glutathione mtb  
 
MGST1 1.90924203 0.02504 microsomal glutathione S-transferase 1 glutathione mtb  
Microarray comparison of wt and aralar KO was carried out as stated in the Material and method section. This table shows the relevant enzymes 
with a significant increase or decrease (Significance Analysis of Microarrays, q-value lower than 0.05, a 2-fold alteration in mRNA levels) in the 
glutathione and aminoacid metabolism, as obtained by ingenuity pathway analysis software.  
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Table S2-  Demyelination-related genes 
 
Name Ratio (KO/WT) q.value Description Pathway Disease 
ASPA 0.42103148 0.00659 aspartoacylase  Asp, ala mtb, Canavan's disease  
Mobp 0.26169276 0.00659331  myelin-associated oligodendrocytic basic protein  [NM_008614]   
Mal 0.27181954 < 0,005  
 myelin and lymphocyte protein, T-
cell differentiation protein (Mal), 
mRNA [NM_010762] 
 neurological disorder 
Mag 0.3906884 < 0,005  
 myelin-associated glycoprotein 
(Mag), mRNA [NM_010758]  
neurological 
disorder 
Plp1 0.4099373 0.0130072 proteolipid protein (myelin) 1 (Plp1), mRNA [NM_011123]  
neurological 
disorder 
Mog 0.43395389 0.01712291 myelin oligodendrocyte glycoprotein (Mog), mRNA [NM_010814]  
neurological 
disorder 
Mbp 0.56516966 0.04149798 myelin basic protein (Mbp), transcript variant 7, mRNA [NM_010777]   
 
ccl3   (demyelination nervous tissue)   
 
Microarray comparison of wt and aralar KO was carried out as stated in the Material and method section. This table shows the relevant proteins 
with a significant increase or decrease (Significance Analysis of Microarrays; q-value lower than 0.05, a 1.8 fold alteration in mRNA levels) 
involved in the myelinization process, as obtained by ingenuity pathway analysis software. 
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Table S3-Aminoacid and metabolite transport 
Name Ratio (KO/WT) q-value Description Pathway  
Slc6a4 5.55695907 0.02761398 Neurotransmitter transporter, serotonin   
Slc3a2 2.34417908 0.02761398 activators of dibasic and neutral amino acid transport Transport of essential aminoacids  
Slc15a3 2.30898427 0.01576956 Slc15a3 Proton-dependent oligopeptide trasnporter  
Slc7a11 2.30802488 0.00516773 cationic amino acid transporter, y+ system; cysteine/glutamate transport Production of glutathione  
Slc7a3 2.26990244 0.01576956 cationic amino acid transporter, y+ system 
Incorporation of arginine, incorporation of 
basic aminoacid, transport of essential 
aminoacids 
 
Slc1a4 1.76166806 0.04058765 glutamate/neutral amino acid transporter Transport of neutral aminoacids  
Slc44a1 0.55988432 0.01712291 solute carrier family 44, member 1  Choline trans membrane transporter activity  
Slc34a3 0.47545072 0.0250446 sodium phosphate   
Slc25a21 0.43614698 0.01712291 mitochondrial oxodicarboxylate carrier Alpha-ketoglutarate transport  
Slc35b3 0.39878825 0.00659331 
Mus musculus 16 days neonate thymus 
cDNA, RIKEN full-length enriched library, 
clone:A130081B15 product:unclassifiable, 
full insert sequence. [AK079504] 
Adenosine 3’-phospho 5’ phosphosulfate 
transporter 2  
Slc45a3 0.29398712 <0.005  solute carrier family 45, member 3   
Slc25a12 0.00768092 <0.005 
Mus musculus solute carrier family 25 
(mitochondrial carrier, Aralar), member 12 
(Slc25a12), mRNA [NM_172436] 
Production of aspartate, malate aspartate 
shuttle, mylein production  
SLC25A13 4.14979757  solute carrier family 25, member 13 (citrin) Malate aspartate shuttle, urea cycle  Type II citrulinemia 
Microarray comparison of wt and aralar KO was carried out as stated in the Material and method section. This table shows the relevant carriers 
with a significant increase or decrease (Significance Analysis of Microarrays , q-value lower than 0.05, a 2-fold alteration in mRNA levels involved 
in the aminoacid and metabolite transport, as obtained by ingenuity pathway analysis software 
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